Share
1,247 Posts.
lightbulb Created with Sketch. 1571
clock Created with Sketch. 01/05/24
07:09
Share
Originally posted by Watmighthavben:
↑
My take on the quarterly activities report is that Imugene appear to be devoting much time to recruiting sites for their clinical trials when perhaps the focus needs to change toward educating oncologists and in turn recruiting patients to them. Historically speaking there appears to be a very slow take up in many of their clinical trials with participants always on the minimal side, despite the large number of sites in play. The FDA allows Imugene to recruit between 3 - 6 patients per cohort in some of their trials, only to find its always closer to 3 enrolled. We only now hear as at May 2023 of one patient enrolled in the much lauded OASIS Trial for solid tumours when close to 90 percent of all cancer patients suffer with solid tumour diagnosis. With the right information surely oncologists in the US let alone Australia would be jumping all over this for their patients. Likewise PD1 Vaxx, the Imprinter Trial and the supposed supply agreement with Roche. What there aren't enough lung cancer patients out there worthy of Professor Kauamaya's already successful B cell vaccine, and a subsequent update in this Quarterly Activities Report?
Expand
Morning Ben, in the March 11 update for OASIS, where Imugene announced the combo cohort was open, Leslie mentioned ovarian, breast and melanoma patients have been dosed. So they have at least 3 dosed for IT. A bile duct patient in the IV mono cohort was announced in Feb, bringing the total number of patients to 4 - that we know of.
(20min delay)